Halog-E Side Effects

Generic Name: halcinonide topical

Note: This page contains information about the side effects of halcinonide topical. Some of the dosage forms included on this document may not apply to the brand name Halog-E.

Not all side effects for Halog-E may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.

For the Consumer

Applies to halcinonide topical: topical application cream, topical application ointment, topical application solution

In addition to its needed effects, some unwanted effects may be caused by halcinonide topical (the active ingredient contained in Halog-E). In the event that any of these side effects do occur, they may require medical attention.

You should check with your doctor immediately if any of these side effects occur when taking halcinonide topical:

Incidence not known
  • Blistering, burning, crusting, dryness, or flaking of the skin
  • irritation
  • itching, scaling, severe redness, soreness, or swelling of the skin
  • redness and scaling around the mouth
  • thinning of the skin with easy bruising, especially when used on the face or where the skin folds together (e.g. between the fingers)

Some of the side effects that can occur with halcinonide topical may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Incidence not known
  • Acne or pimples
  • burning and itching of the skin with pinhead-sized red blisters
  • burning, itching, and pain in hairy areas, or pus at the root of the hair
  • increased hair growth on the forehead, back, arms, and legs
  • lightening of normal skin color
  • lightening of treated areas of dark skin
  • reddish purple lines on the arms, face, legs, trunk, or groin
  • softening of the skin

For Healthcare Professionals

Applies to halcinonide topical: topical cream, topical ointment, topical solution

Local

Skin atrophy may become evident within one to two months of use and is due to the inhibitory effect of corticosteroids on collagen formation. Skin on the face, axillae, and groin appears to be most susceptible to the adverse long-term effects of topical halcinonide. Use of high potency topical corticosteroids on these areas should be minimized or avoided.

Topical corticosteroid use may impair local immune response rendering the skin more susceptible to infections. Folliculitis has occasionally been reported.

Perioral dermatitis or rosacea-like dermatitis has occurred in patients treated with potent topical corticosteroids who are of seborrheic skin type. This condition may flare temporarily upon discontinuation of topical steroids, prompting patients to continue their use. If topical corticosteroids are discontinued, this flare and the initial dermatitis generally resolves over a few weeks. Worsening of psoriasis has occurred in a few patients.

Local side effects have commonly included burning, itching, erythema, dryness, or irritation, especially when applied to denuded skin. Long-term use of topical corticosteroids has resulted in skin atrophy and thinning, and the development of striae, telangiectasias, subcutaneous hemorrhage, and easy bruising and bleeding. Allergic contact dermatitis has occasionally been reported.

Endocrine

Endocrine side effects have included suppression of the hypothalamic-pituitary-adrenal axis. This was more likely when higher potency topical corticosteroids were used over extensive areas and when occlusive dressing were used. In addition the ointment and emollient cream formulations of halcinonide generally provided better penetration, and thus, higher risk of adrenal suppression.

Adrenal suppression has been demonstrated in patients with normal skin using halcinonide 0.1% cream with occlusion and in patients with diseased skin (psoriasis) not using occlusion. Plasma cortisol concentrations returned to normal within one to two days following discontinuation of the drug.

If halcinonide is to be used for an extended period of time, adrenal function should be evaluated periodically. Supplemental systemic steroids may be necessary during times of stress.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide
(web2)